abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 08월 28일 16시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

Restriction Fragment Mass Polymorphism (RFMP); A Promising New Theranostic Platform Based on MALDI-TOF Mass Spectrometry

등록일
2008년 8월 28일 11시 25분 46초
접수번호
1615
발표코드
금14J4심 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
금 11시 : 20분
발표형식
심포지엄
발표분야
생명화학 - Omics & Personalized Medicine I
저자 및
공동저자
홍선표
진매트릭스 중앙연구소, Korea
Genetic differences contributed to phenotypic diversity of humans or pathogens, including variation in disease susceptibility and drug response. The genotypic analysis to identify the polymorphisms that differentiate one individual or strain from another has become increasingly important as a prognostic measure of disease courses and to enable choice of more efficacious therapeutic or preventive options based on individual genetic makeup, since especially the post genomic research has increased the knowledge about the inherited basis for the interindividual differences and aid in finding the potential intervention therapies at the molecular level. Recently, as a fusion of drug therapy and diagnostics, theranostics is emerging with the purpose of the use of molecular testing to subtype the disease, to choose the correct treatment regime and to monitor the patient response to therapy. We describe a novel MALDI-TOF MS based genotyping strategy, termed Restriction Fragment Mass Polymorphism (RFMP) that is suitable for genotyping variations in a simple, accurate, and high-throughput manner. The assay is based on polymerase chain reaction (PCR) amplification and mass measurement of oligonucleotides containing a polymorphic base, to which a type IIS restriction endonuclease recognition was introduced by PCR amplification. The RFMP assay proved to be an accurate and reliable tool for detection of antiviral-resistant mutations in hepatitis B virus, hepatitis C virus genotypes and other genotype applications of clinical relevance. The simplicity, accuracy, and amenability to semi-quantitative and high-throughput screening analysis should make the RFMP assay suitable for reliable theranostic platform in clinical laboratories as well as large-scale association study.

상단으로